Pneumococcal

CDC Pink Book on Pneumococcal Disease
http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/pneumo.pdf

Package Inserts
Pneumococcal (PCV)- recommended for those aged 2 months to 18 years
http://www.immunize.org/packageinserts/pi_pcv7.asp
Pneumococcal (PPSV)- recommended for those aged 2 and older with a high-risk of infection
http://www.immunize.org/packageinserts/pi_ppsv.asp

Pneumococcal Information
http://www.nvic.org/Vaccines-and-Diseases/Pneumococcal.aspx

Signs and Symptoms of Pneumococcal Disease
http://www.medicalnewstoday.com/info/pneumococcal-disease/signs-and-symptoms.php

STUDIES:

Vaccination against a bacterium called pneumococcus for preventing middle ear infection
http://www.cochrane.org/CD001480/ARI_vaccination-against-a-bacterium-called-pneumococcus-for-preventing-middle-ear-infection

Streptococcus pneumoniae colonisation in children and adolescents with asthma: impact of the heptavalent pneumococcal conjugate vaccine and evaluation of potential effect of thirteen-valent pneumococcal conjugate vaccine (2016)
https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-016-1335-3

Invasive Pneumococcal Disease After Implementation of 13-Valent Conjugate Vaccine
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4187237/

Sub-Optimal Response to PCV-13 Vaccinations Among Children with Recurrent Sinusitis and Otitis Media
http://search.proquest.com/openview/701e8a51b24368a4c00d8a29c60105bf/1?pq-origsite=gscholar

Changing serotypes causing childhood invasive pneumococcal disease, Massachusetts, 2001-2007 (published 2010)
Invasive disease from pneumococcal serotypes in vaccine decreased, but invasive disease from serotypes not in the vaccine increased.
http://www.ncbi.nlm.nih.gov/pubmed/19935447

Epidemiological Evidence for Serotype-Independent Acquired Immunity to Pneumococcal Carriage
http://jid.oxfordjournals.org/content/200/1/99.full

A Trial of a 9-Valent Pneumococcal Conjugate Vaccine in Children with and Those without HIV Infection
Excerpt: “We did find an increase in asthma among vaccine recipients, which has not been reported to date in previous studies of the 7-valent formulation in the U.S. An increase in asthma may be expected, given the hygiene hypothesis of decreased childhood infections. The increased incidence of asthma among vaccinated children in our study should be seen in the context of a reduction in the risk of pneumonia among vaccinated children.”
http://www.nejm.org/doi/full/10.1056/NEJMoa035060#t=articleResults

Vaccination with PCV-7 was associated with an increase in a strain not covered by the vaccine in vaccinated individuals compared to unvaccinated.
http://www.ncbi.nlm.nih.gov/pubmed/20823436

“The one notable safety finding was that hospitalization for otitis media occurred more frequently in PCV7 recipients than in comparison vaccine recipients, which is puzzling given that another clinical trial found that PCV7 is effective in preventing otitis media.”
http://www.who.int/bulletin/volumes/86/5/07-048025/en/

Healthcare utilization and cost of pneumococcal disease in the United States
http://www.ncbi.nlm.nih.gov/pubmed/21397721

Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children. (2013)
Excerpt: “The possible association between PCV13 and Kawasaki disease may deserve further investigation.”
http://www.ncbi.nlm.nih.gov/pubmed/23579258

Advertisements